INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 410m ago
HOUSE PTR9m ago
SEC 13F9m ago
ROBINHOOD CHAIN9m ago
SEC FORM 4/Tax withholdingVerified data

Muzzey Dale reported MYGN

Chief Scientific Officer · MYRIAD GENETICS INC · Common Stock

Side
F
Value
$2,571
Shares
418
Price
$6.15
Executed
Jan 1, 2026
Disclosed
Jan 2, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 1 executedJan 2, 2026 disclosed

MYGN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$3K reported value · 0.2% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MYGN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    FL
    Fox Jennifer LynneChief Legal & Corp Strategy
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    39.4K sh
    		Nov 1, 2026Nov 2, 2026
    traded Nov 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$10K
    2,555 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    21
    SV
    Sikri VishalEVP, Commercial
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    257.7K sh
    		Sep 16, 2026Sep 17, 2026
    traded Sep 16, 2026
    		+1dSEC FORM 4

    Evidence

    15
    FL
    Fox Jennifer LynneChief Legal Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$14K
    4,398 sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    9
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$27K
    8,761 sh
    		Aug 16, 2026Aug 17, 2026
    traded Aug 16, 2026
    		+1dSEC FORM 4

    Evidence

    9
    DJ
    Donnelly Brian JChief Commerical Officer
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A$20K
    5,000 sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    12
    KR
    Kumar RashmiDirector
    MYGNMYRIAD GENETICS INC
    Open-market sale · 10b5-1 plan
    		SELL$67K
    15.0K sh
    		Jun 8, 2026Jun 9, 2026
    traded Jun 8, 2026
    		+1dSEC FORM 4

    Evidence

    21
    DS
    Davis Mark StevenDirector
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    59.7K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    JR
    Jampa RajChief Technology Officer
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    251.9K sh
    		Jun 1, 2026Jun 2, 2026
    traded Jun 1, 2026
    		+1dSEC FORM 4

    Evidence

    19
    DJ
    Donnelly Brian JChief Commerical Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$269K
    56.0K sh
    		May 1, 2026May 4, 2026
    traded May 1, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VM
    Verratti MarkChief Operating Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$5,249
    1,069 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MD
    Muzzey DaleChief Scientific Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$4,645
    946 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$2,514
    549 sh
    		Mar 22, 2026Mar 23, 2026
    traded Mar 22, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MD
    Muzzey DaleChief Scientific Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$9,247
    2,019 sh
    		Mar 22, 2026Mar 23, 2026
    traded Mar 22, 2026
    		+1dSEC FORM 4

    Evidence

    21
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    206.2K sh
    		Mar 12, 2026Mar 16, 2026
    traded Mar 12, 2026
    		+4dSEC FORM 4

    Evidence

    9
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$10K
    2,192 sh
    		Mar 15, 2026Mar 16, 2026
    traded Mar 15, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MD
    Muzzey DaleChief Scientific Officer
    MYGNMYRIAD GENETICS INC
    Grant or award
    		A—
    173.2K sh
    		Mar 12, 2026Mar 16, 2026
    traded Mar 12, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MD
    Muzzey DaleChief Scientific Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$39K
    8,288 sh
    		Mar 14, 2026Mar 16, 2026
    traded Mar 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    Muzzey DaleChief Scientific Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$22K
    4,783 sh
    		Mar 15, 2026Mar 16, 2026
    traded Mar 15, 2026
    		+1dSEC FORM 4

    Evidence

    9
    WR
    Wheeler Benjamin RichardChief Financial Officer
    MYGNMYRIAD GENETICS INC
    Tax withholding
    		F$4,087
    877 sh
    		Mar 15, 2026Mar 16, 2026
    traded Mar 15, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001922964-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 1, 2026
    Published
    Jan 2, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Muzzey Dale
    Role
    Chief Scientific Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    MYRIAD GENETICS INC
    Ticker
    MYGN
    Shares
    418
    Price per share
    $6.15
    Value
    $2,571
    Execution date (reported)
    Jan 1, 2026
    Owned after transaction
    170.2K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 418
    • Price: $6.15

    = $2,571

    What this establishes

    Muzzey Dale filed this Form 4 reporting a tax withholding of MYGN on Jan 1, 2026. It became public on Jan 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Muzzey Dalecik:0001922964
    Issuer
    MYRIAD GENETICS INCcik:0000899923

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.